OUR TEAMScientists and builders, working on the same problem.
Meet the people shaping Ravel Genetics, from core technology and multi-omics data to brand, scientific direction, and regulatory strategy.
Founders & leadership
Rachel Montel Hayes, PhD
Founder & CEO
Dr. Hayes is a geneticist specializing in genomics and precision medicine. Her work has focused on biomarker discovery to support precision diagnostics, with experience spanning genetic testing and integrative health. She founded Ravel Genetics to address the need for preventive solutions in today's health landscape and to help usher in the era of precision medicine.
Christopher Mason, PhD
Co-Founder & Chief Scientific Officer
Dr. Mason is the WorldQuant Professor of Genomics and Computational Biomedicine at Weill Cornell Medicine, where he directs the Initiative for Quantitative Prediction. He has published 230+ peer-reviewed papers, including in Nature, Science, and Cell. He served as a principal investigator for the NASA Twins Study and has co-founded multiple biotech companies. His research spans functional genomics, epigenomics, metagenomics, and space biology.
Colin Hayes
Co-Founder · Brand & Business Strategy
Colin shapes how Ravel shows up in the world. With a background in engineering operations and technology management, he brings a rare blend of technical fluency and creative instinct to Ravel's brand and commercial strategy, leading visual identity, messaging, and market positioning.
Science & engineering
Evan Sticca, PhD
Bioinformatics
Dr. Sticca is a computational biologist with expertise in quantitative methods and genomic data architecture. He completed his PhD at the University of Colorado Anschutz Medical Campus and has held positions at Cornell University, The Rockefeller University, and Castle Biosciences, where he serves as a Data Architect supporting molecular diagnostics. At Ravel, he leads the design of the platform's multi-omics data integration infrastructure.
Kyle Malvey, MBA
Software Development
Kyle leads the design and delivery of the enterprise-grade architecture behind Ravel's platform, aligning technology strategy with the product roadmap. With a track record of driving digital transformation, he ensures the platform is scalable, secure, and built for long-term growth.
Advisors
P. Daniel Lin, MD PhD
Scientific Advisor
Dr. Lin is a physician-scientist trained in psychiatry and genetic epidemiology, and an Associate Professor at Saint Louis University with an adjunct appointment at the University of New South Wales. His work centers on translating biological and population-level data into clinically actionable insights, and he has led multidisciplinary research on the genetic, environmental, and socioeconomic drivers of neuropsychiatric conditions using large-scale datasets, clinical trials, and machine learning.
Monica Gertz, PhD
Scientific Advisor
Dr. Gertz is a biomedical scientist and health-tech entrepreneur affiliated with Cornell Tech and Weill Cornell Medicine. She completed her postdoctoral training at Weill Cornell and was awarded first place in the Accelerating BioVenture Innovation competition for her work on an AI-powered speech restoration device. She advises Ravel on scientific strategy and commercialization.
Bruce Paolella, MBA
Regulatory Advisor
Bruce is a Principal Consultant at Opus Regulatory with over 20 years of experience in pharmaceutical regulatory affairs. He has held senior regulatory roles at Indivior, Reckitt Benckiser Pharmaceuticals, and TherapeuticsMD, where he served as VP of Regulatory Advertising and Promotion. His expertise spans regulatory strategy, FDA compliance, and commercialization. At Ravel, he leads regulatory strategy and a clear path to launch.